Jun 6 |
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
|
Jun 5 |
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
Jun 3 |
EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC
|
May 31 |
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
|
May 30 |
Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now
|
May 29 |
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
|
May 28 |
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
|
May 28 |
When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable?
|
May 18 |
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
|
May 13 |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
|